🏠 Home › Patent Linkage and Drug Approval in China: A Guide for Foreign Pharmaceutical Companies

Patent Linkage and Drug Approval in China: A Guide for Foreign Pharmaceutical Companies

📅 2026-06-01 🏷️ Patent

## Patent Linkage and Drug Approval in China: A Guide for Foreign Pharmaceutical Companies On June 1, 2021, China's fourth amended Patent Law took effect, with the most notable institutional innovation being the formal codification of the drug patent linkage system. This system bridges drug marketing approval (NMPA/CDE review) with patent dispute resolution (judicial/administrative) and has been called China's version of the "Hatch-Waxman Act." For both innovator and generic drug companies seeking to enter the Chinese market, understanding this system is essential for compliant operations. This article provides a systematic interpretation of the core rules, operational procedures, and risk points of China's drug patent linkage system from a practical foreign pharmaceutical enterprise perspective. ## I. Institutional Framework: The Bridge System of Laws and Regulations The legal foundation of China's drug patent linkage system consists of three tiers. The top tier is Article 76 of the Patent Law, which establishes at the statutory level the mechanism connecting drug marketing authorization applications with patent dispute resolution. The middle tier is the Implementing Measures for the Early Resolution Mechanism of Drug Patent Disputes (NMPA Announcement No. 89 of 2021), which refines the specific operational rules. The bottom tier comprises the Administrative Adjudication Measures for the Early Resolution Mechanism of Drug Patent Disputes and relevant judicial interpretations, which respectively set forth the procedures for two resolution pathways: administrative adjudication and judicial litigation. The core philosophy of this three-tier structure is "early resolution" — resolving patent disputes before, rather than after, a generic drug enters the market, thereby reducing the risk of patent infringement. Foreign pharmaceutical companies should note that China's drug patent linkage system does not simply copy all rules from the U.S. Hatch-Waxman Act. Instead, it has been localized to fit the realities of China's administrative and judicial systems. For example, China's system adopts a "dual-track administrative and judicial" dispute resolution model, allowing parties either to file a lawsuit with the Beijing Intellectual Property Court or to request an administrative adjudication from CNIPA. The following table compares key differences between China's drug patent linkage system and the U.S. Hatch-Waxman system: | Dimension | China Drug Patent Linkage System | U.S. Hatch-Waxman System | |---|---|---| | Legal Basis | Patent Law Art. 76 + ministerial regulations | 21 U.S.C. §355(j) | | Dispute Resolution Body | Beijing Intellectual Property Court or CNIPA | Federal District Courts | | Patent Registry Platform | China Listed Drug Patent Information Registration Platform | FDA Orange Book | | Generic Drug Certification Types | Class 1 / Class 2 / Class 3 / Class 4 | Paragraph I / II / III / IV | | Approval Stay Period | 9 months (chemical drugs) | 30 months | | First Generic Exclusivity | 12 months | 180 days | | Biosimilar Applicability | Only reference product patents registrable | Applicable (BPCIA) | ## II. Patent Registration: Core Rules of the Listed Drug Patent Information Registration Platform China's Listed Drug Patent Information Registration Platform (hereinafter the "Registration Platform") is the cornerstone of this system. Innovator drug companies should register relevant patent information on this platform as early as possible, because unregistered patents cannot invoke the patent linkage process during subsequent generic drug approval. The Registration Platform covers the following types of patents: active ingredient compound patents for chemical drugs, pharmaceutical composition patents containing active ingredients, and medical use patents. Traditional Chinese medicine patents and biological product patents are also subject to registration rules. Notably, intermediate patents, metabolite patents, crystal form patents, and preparation method patents are currently outside the scope of registration. For drugs marketed in China by foreign pharmaceutical enterprises, each relevant patent should be separately registered on the Platform. Each patent registration requires submission of the patent number, patent name, patent holder, patent term, patent type, and a description of the correspondence between the patent and the drug. **Key operational points for foreign pharmaceutical companies in the patent registration phase:** 1. Prioritize registration of core patents — compound patents and indication patents should be registered first, as the foundation for subsequent rights claims depends on registration information 2. Update patent status in a timely manner — changes such as patent term extensions, patent invalidation declarations, and patent assignment should be updated on the registration within 30 working days 3. Pay attention to registration windows — for chemical drugs, registration should be completed as soon as possible after NDA approval; for biological products, after the reference product is approved for marketing 4. Prepare Chinese-language versions of patent documents — the Registration Platform primarily uses a Chinese-language interface, and supporting documents such as patent specifications require Chinese translations 5. Engage Chinese patent agency services — patent agencies recognized by CNIPA are more familiar with the registration process and document requirements ## III. Generic Drug Approval and the Four Types of Patent Certifications When a generic drug company submits a drug marketing authorization application to NMPA/CDE, it must make a certification for each relevant patent registered on the Platform. The certifications fall into four categories: **Class 1 Certification:** No relevant patent exists on the Registration Platform. Applicable where a generic drug is developed after the patent term has expired. **Class 2 Certification:** The relevant patent on the Registration Platform has lapsed or been declared invalid. The generic drug company must provide proof of patent expiry — typically a patent term expiry certificate or an invalidation decision issued by CNIPA. **Class 3 Certification:** The generic drug company undertakes not to market the generic drug before the expiry of the relevant patent term. This certification effectively acknowledges the validity of the patent and the risk of infringement. The generic drug company merely seeks "early administrative approval" (Bolar exemption) and may only market the drug after the patent expires. **Class 4 Certification:** The generic drug company asserts that the relevant patent on the Registration Platform should be declared invalid, or that its generic drug does not fall within the scope of the patent. This is the most contentious and legally risky type of certification — once a Class 4 certification is made, the generic drug company must, within 20 working days, notify the patent holder of the certification along with the corresponding legal rationale. For foreign pharmaceutical enterprises (patent holders), upon receiving a Class 4 certification notice, they should immediately initiate response procedures. The patent holder must decide within 45 days of receiving the notice whether to file a lawsuit or request an administrative adjudication. The 45-day window is calculated from the date the generic drug company issues the notice, including mail delivery time. If proceedings are not initiated within this period, CDE will no longer wait and will proceed with the technical review of the generic drug. ## IV. The Nine-Month Approval Stay: Dual-Track Relief Paths Within 45 days of receiving a Class 4 certification notice, a foreign pharmaceutical enterprise may choose either of the following two relief paths: **Path One: Judicial Litigation.** File a drug patent linkage lawsuit with the Beijing Intellectual Property Court. Pursuant to the Supreme People's Court Provisions on Several Issues Concerning the Trial of Drug Patent Linkage Dispute Cases, the court should hear the case promptly after acceptance. The trial period for such cases generally ranges from 6 to 9 months. The judgment may be appealed to the Intellectual Property Tribunal of the Supreme People's Court. **Path Two: Administrative Adjudication.** Request CNIPA to render an administrative adjudication on patent validity or infringement. CNIPA's drug patent linkage administrative adjudication process is relatively efficient, generally issuing a decision within 9 months of acceptance. If dissatisfied with the administrative adjudication, the party may file an administrative lawsuit. Once the patent holder initiates either of the above proceedings, CDE will impose a maximum 9-month stay on the review of the corresponding generic drug. During this period, CDE suspends the technical review of the generic drug, pending the outcome of the judicial judgment or administrative adjudication. Upon expiry of the 9-month period, CDE will resume review regardless of whether the dispute has been resolved — meaning that if no result is reached within 9 months, the generic drug may be approved while the patent dispute remains unsettled. Strategic recommendations for foreign pharmaceutical enterprises to leverage the 9-month stay period: - Prepare both litigation and administrative adjudication plans in parallel, prioritizing the faster path - Act promptly within the 45-day initiation period to maximize the effective duration of the 9-month stay - Collect and submit comprehensive patent technical comparison evidence, particularly claim-to-product comparison analyses between the patent and the generic drug's technical solution - Monitor whether CDE requires corrections due to incomplete materials — any procedural deficiency may delay the start date of the stay period ## V. First Generic Market Exclusivity: The 12-Month Incentive and Countermeasure Mechanism Another important design feature of China's drug patent linkage system is the first generic market exclusivity period. Under the regulations, the first generic drug company to successfully challenge a patent and obtain marketing approval is entitled to a 12-month period of market exclusivity. During these 12 months, CDE will not approve any other generic versions of the same drug for marketing. Foreign pharmaceutical companies need to understand the far-reaching implications of this mechanism. The first generic exclusivity period significantly increases the incentive for generic companies to file Class 4 certifications — because the first generic company to successfully challenge a patent will enjoy exclusive market access for a one-year window, yielding substantial economic returns. This means that foreign innovator drug companies face significantly increased pressure from patent challenges. Strategies for responding to the first generic exclusivity period include: Similar to Orange Book defense strategies for innovator drugs, foreign pharmaceutical companies should establish a tiered defense system. Build multiple patent protection barriers around core patents (compound patents, basic indication patents), making it more difficult for generic companies to challenge multiple patents simultaneously. Additionally, "secondary patents" (such as formulation patents, crystal form patents, and new dosing regimen patents) can be used to extend the overall protection lifecycle — although these patents fall outside the scope of registrable patents under the drug patent linkage system, they can serve as the basis for post-market infringement litigation. ## VI. Practical Recommendations and Risk Warnings **First, the registration window is irreversible.** Failure to register core patents within 30 days of drug approval will permanently forfeit the opportunity to invoke the patent linkage process. Foreign pharmaceutical companies should complete the organization and translation of patent information before a new drug is approved for marketing in China, and complete registration immediately upon approval. **Second, the strategy of choosing between administrative adjudication and judicial litigation.** CNIPA's administrative adjudication may be more efficient than the Beijing Intellectual Property Court, but CNIPA's adjudication is limited to "technical facts" (patent validity and infringement) and cannot issue judgments on matters such as damages. Therefore, for drugs involving significant markets, it is recommended to prepare a parallel patent infringement lawsuit plan alongside the request for administrative adjudication. **Third, pay attention to China's Patent Term Extension (PTE) policy.** The 2021 new Patent Law also introduced a drug patent term compensation system, with a compensation period of no more than 5 years and a total effective patent term not exceeding 14 years. After a patent term extension, the patent term information on the Registration Platform should be updated promptly; otherwise, a generic company may argue that its certification was made in reliance on an incorrect term. **Fourth, information asymmetry risk.** China's Registration Platform is self-maintained by enterprises and lacks an official substantive review process comparable to the U.S. Orange Book. Foreign pharmaceutical companies should designate personnel to regularly check their own patent registration status to confirm that no registration information has been omitted due to system issues or operational errors. At the same time, subscribing to CDE announcements is recommended to monitor whether any Class 4 certifications have been filed concerning their own products. For further consultation on the specific operations of China's drug patent linkage and approval system — including patent registration, certification response, and litigation strategy development — please contact the WeRights professional team. Follow the Telegram channel @token_1_com for more updates on China's intellectual property policies and practical guidance.

📩 Need Help with Your IP Registration?

👉 Message @token_1_com